TSS Home Comfort, an established provider of residential heating, cooling, and air purification services in Boise and the Treasure Valley, proudly reaches 165 5-star Google ratings. This achievement reflects the company’s consistent delivery of exceptional service and quality workmanship, earning the trust and confidence of homeowners across the region.

“TSS Home Comfort has built its reputation on trust, quality workmanship, and customer service,” said Steve Miller, President of TSS HVAC Services & TSS Home Comfort. “Every review we receive is a reflection of our team’s dedication to doing the job right the first time. We’re honored to be recognized by so many homeowners, and we will continue to raise the bar for HVAC service in Boise.”

TSS Home Comfort’s sustained 5-star performance underscores its commitment to professionalism, punctuality, and honesty. Every technician is fully licensed, background-checked, and undergoes rigorous annual training to ensure the highest standard of safety, accuracy, and customer care.

TSS Home Comfort’s handpicked technicians are passionate about providing a pleasant, hassle-free experience from start to finish. Arriving promptly in clean uniforms and fully stocked service vehicles, they complete each task efficiently so homeowners can return to their day with minimal disruption.

The company’s upfront, straightforward pricing and policy of never recommending unnecessary services set it apart in the HVAC industry. Customers can expect only the solutions they truly need, backed by the team’s decades of expertise.

Comprehensive Services & Local Reach

Serving Boise and the Treasure Valley, TSS Home Comfort provides heating, cooling, and air purification solutions, including:

  • HVAC Installation & Replacement – Energy-efficient systems for year-round comfort
  • Repairs & Emergency Service – 7 days a week across the Treasure Valley
  • Total Care Club Maintenance Plan – Maximizing system performance and lifespan
  • Indoor Air Quality Solutions – Advanced filtration and purification options

Contact TSS Home Comfort

To learn more about TSS Home Comfort or to schedule service, call (208) 908-4330 or visit https://www.tsshomecomfort.com.

TSS Home Comfort
1712 S Roosevelt St, Boise, ID
Phone: (208) 908-4330

About TSS Home Comfort

TSS Home Comfort specializes in heating, cooling, and air purification services for homeowners in Boise and the Treasure Valley. Known for its customer service, professionalism, and transparent pricing, TSS Home Comfort is committed to keeping homes comfortable year-round.

Media Contact

Organization: TSS Home Comfort

Contact Person: Natalie Martin

Website: https://www.tsshomecomfort.com/

Email: Send Email

Contact Number: +12089084330

Address:1712 S Roosevelt St

City: Boise

State: ID

Country:United States

Release id:26035

The post TSS Home Comfort Reaches 165 Perfect 5-Star Google Reviews Cements Reputation as Best HVAC Company in Boise appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

New York, USA — In a city where every inch of space is a precious resource, Shaoul Ohana Architects is setting a new standard for how architecture and landscape design can work together to create sustainable, beautiful, and functional urban spaces. Through their innovative approach to NYC landscape architecture and construction design, the firm is shaping the future of the built environment with projects that are as environmentally responsible as they are visually compelling.

More than just an architectural practice, Shaoul Ohana Architects sees the city as a living organism — one where buildings, public spaces, and green areas must be designed in harmony. This philosophy underpins every project, from rooftop gardens in the heart of Manhattan to adaptive reuse developments in historic districts. Their portfolio reflects a consistent commitment to improving both the ecological footprint and the livability of New York’s urban landscape.

Read more about their vision here: Shaoul Ohana Architects: A Vision for NYC Landscape Architecture and Construction Design.

Reimagining Green Spaces in a Dense City

Shaoul Ohana Architects believes that green space should be treated as vital infrastructure. In a metropolis known for its skyscrapers and fast pace, their designs bring nature directly to where people live and work. Whether it’s transforming a barren rooftop into a lush community garden, installing vertical plant walls on residential towers, or creating pedestrian-friendly streetscapes, the firm’s goal is to make nature an everyday experience for New Yorkers.

These green interventions are not purely decorative — they are designed to manage stormwater, improve air quality, reduce heat island effects, and encourage biodiversity. By integrating native plants and sustainable irrigation systems, the firm ensures that its designs remain resilient in New York’s challenging climate while reducing environmental impact.

Construction Design That Stands the Test of Time

Shaoul Ohana Architects takes an equally forward-thinking approach to construction design. They focus on creating buildings that are adaptive, energy-efficient, and equipped with the latest smart technologies. Each project is tailored to its neighborhood context, balancing bold design with sensitivity to surrounding architecture.

Key principles in their construction philosophy include:

  • Adaptive Reuse: Transforming historic structures into modern, high-performing spaces while preserving their character.
  • Sustainability: Incorporating renewable energy systems, optimized building envelopes, and locally sourced materials to reduce carbon footprints.
  • Future-Proofing: Designing with modularity and flexibility so buildings can evolve alongside technological advancements and urban needs.
  • Smart Integration: Using intelligent systems for lighting, climate control, and security to improve efficiency and comfort.

Design for People and Communities

At the heart of the firm’s work is a focus on people. Shaoul Ohana Architects engages closely with communities, stakeholders, and clients to ensure each design serves real needs — whether that’s providing accessible public plazas, creating quiet green retreats, or designing mixed-use spaces that bring together living, working, and leisure in one place.

“Our work is about more than buildings and parks,” said Shaoul Ohana, Founder and Principal Architect. “It’s about shaping the way people experience the city. Every project is an opportunity to strengthen communities, support the environment, and leave a lasting positive impact on New York City.”

A Growing Influence on New York’s Urban Future

As the city faces challenges from climate change, population growth, and shifting lifestyles, the role of innovative architecture and thoughtful urban design becomes even more crucial. Shaoul Ohana Architects is at the forefront of this transformation, creating projects that are not only beautiful and functional but also resilient and sustainable.

From the initial concept to the final detail, the firm combines creativity with precision, ensuring every project contributes to a more vibrant, livable, and ecologically balanced city. With a reputation for integrity and innovation, they are shaping the future of New York’s architectural and landscape identity.

About Shaoul Ohana Architects

Shaoul Ohana Architects is a New York-based architecture and design firm specializing in the seamless integration of landscape architecture and construction design. Founded by Shaoul Ohana, the firm is dedicated to creating spaces that balance innovation, sustainability, and community engagement. Their portfolio spans adaptive reuse projects, high-performance new constructions, urban green space design, and smart building integration. By blending cutting-edge technology with environmental stewardship, Shaoul Ohana Architects continues to shape the urban future of New York City.

Media Contact

Organization: Shaoul Ohana Architects

Contact Person: Shaoul Ohana

Website: https://www.academia.edu/130494427/Shaoul_Ohana_Architects_A_Vision_for_NYC_Landscape_Architecture_and_Construction_Design

Email: Send Email

Country:United States

Release id:32590

The post Shaoul Ohana Architects Unveils Bold Vision for Transformative Architectural Design in New York City appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

The9bit, a dynamic gaming platform that transforms everyday player activities into rewarding experiences, is making waves at Coinfest Asia 2025, Asia’s premier Web3 festival held in Bali, Indonesia. As an official sponsor, the platform is inviting Web3 enthusiasts, gamers, and industry leaders to connect at its dedicated booths, participate in a high-profile side event, and join an ongoing $1 million giveaway campaign celebrating its launch month.

Set for August 21-22, Coinfest Asia 2025 is gearing up to be a thrilling hotspot for innovation and connections, attracting thousands of enthusiastic attendees from around the world. The9bit’s standout presence highlights its gamer-first ethos, seamlessly merging authentic IP from partners like Capcom with engaging community tools. Head over to the booth in “The Arena” for an eye-popping game totem with hands-on demos—grab cool swag like branded beersleeves and handheld fans to beat the Bali heat while soaking up the fun. Over in “The Main Exhibition Hall,” get ready for high-energy activities offering chances to score up to $500 USD in prizes, plus exciting game CDKeys for hits like Monster Hunter and Resident Evil. These perks perfectly embody the9bit’s mantra of “real activity = real value,” making every visit a rewarding adventure.

Amping up the festival vibe even further, the9bit is co-hosting an unmissable beachside extravaganza on August 23: the “Sunset Labubu Party: Monster Gamefi Soft Launch Event.” Held against the breathtaking shores of Lyma Beach in Bali, this exclusive bash runs from 5:00 PM to 11:00 PM and is set to attract about 200 top KOLs, influencers, traders, and investors from South East Asia and more. Expect a dynamic lineup with the Monster GameFi soft launch ceremony, insightful networking, and spotlight presentations—including a dedicated 9 BIT slot from 8:15 PM to 8:45 PM. Standout moments include a $1,000 USD giveaway featuring cash and Labubu V3 collectibles, refreshing welcome drinks, branded goodie bags, and a lively social media contest. Spots are limited and require host approval—lock in yours now at https://lu.ma/erc4uj2t.

Amid these festivities, the9bit’s $1 million giveaway remains in full swing, marking its official launch month with substantial prizes for participants. The platform recently distributed $100,000 USD to phase 1 winners, leaving $900,000 USD up for grabs throughout August. Gamers can dive in by completing missions, such as liking and reposting promotional content, to enter lucky draws and earn loyalty points redeemable for games, top-ups, or other perks. For full details, users are directed to the official Spaces section on the9bit.com or the platform’s X account at x.com/the9bit, where updates on winners and entry methods are shared regularly.

As the9bit continues to bridge Web2 spending with innovative rewards, its activities at Coinfest Asia 2025 position it as a key player in the evolving gaming landscape. Whether through booth interactions, the beachside networking event, or the lucrative giveaway, the platform is inviting the community to “top-up, play, and earn—finally.” 

For more on the9bit’s ecosystem, including its 100+ casual games and Spaces for social mining, visit the9bit.com.

Media Contact

Company Name: the9bit

Contact Person: the9bit Marketing Team

Email: marketing@the9bit.com

Website: https://the9bit.com/

Country: Singapore

Verified licensing, fast delivery, and exceptional service from platforms like Gosoftware are helping users make smarter, safer software purchases in 2025. 

Middletown, DE, 19th August 2025, ZEX PR WIRE, As more consumers shift their tech purchases online, confidence in digital software retailers has reached record-breaking levels in 2025. With security concerns, product authenticity, and pricing transparency long-standing issues in the industry, this surge in trust reflects a broader shift toward verified platforms that deliver legitimate software without compromise.

A key player in this transformation is Gosoftware, a US-based authorized Microsoft reseller known for its instant delivery, affordable pricing, and unmatched customer support. Offering a full range of Microsoft products—from Microsoft Office 2024 Home & Business to Windows Server 2025 and Microsoft Visio Professional 2021—Gosoftware has served over 100,000 users worldwide and received more than 5,000 verified 5-star reviews.

“The old model of lining up at a retail store or risking a license key from an unverified site is becoming obsolete,” said a representative from Gosoftware. “Customers today want authentic, fast, and secure software—and we’re proud to deliver that, backed by our status as a certified Microsoft partner.”

Consumer feedback shows a noticeable uptick in demand for one-time software licenses, with users increasingly choosing to buy Microsoft Office 2024, purchase Microsoft Excel, or buy antivirus software without the burden of recurring fees. For freelancers, small businesses, and remote professionals, the appeal lies in ownership, simplicity, and long-term value.

Beyond just Microsoft Office, Gosoftware also supports users looking to buy antivirus software online, purchase Visio Professional 2021, or explore best-selling options like Microsoft Office 2021 for Mac download and Microsoft Office 2024 for Mac.

The rise in online trust also highlights the value of transparency. Gosoftware’s site displays product details, compatibility, and installation instructions, minimizing confusion and ensuring buyers get what they expect. Every purchase comes with instant email delivery, an installation warranty, round-the-clock live chat, and phone support.

In an era dominated by cloud subscriptions and complex licensing agreements, platforms like Gosoftware offer a refreshing alternative: upfront pricing, absolute ownership, and responsive service. Whether looking to buy MS Office 2024, purchase MS Office for Mac, or take advantage of antivirus software sales, today’s users can trust that they’re getting real value, not risky shortcuts.

About Gosoftware

Gosoftware is an authorized Microsoft partner (Partner No. 6285889) offering genuine, one-time purchase software with instant digital delivery. With a catalog that includes Microsoft Office, Windows Server, Microsoft Excel, Visio Professional, and leading antivirus solutions, Gosoftware is trusted by more than 100,000 users globally. Every license is legitimate, every product is verified, and every customer receives expert support.

Contact

Website: https://gosoftwarebuy.com 

Email: support@gosoftwarebuy.com 

Address: 651 N Broad St, Middletown, DE 19709, USA

Leading Software Retailer Unveils Enhanced Security Standards, Transparent Licensing, and Expanded Support to Better Serve Customers in 2025

Middletown, DE, 19th August 2025, ZEX PR WIRE, Gosoftware, a trusted name in the online software retail space, has announced a series of new initiatives aimed at reinforcing its core promise: delivering secure, affordable, and fully licensed software to individuals and businesses worldwide. These strategic upgrades reflect Gosoftware’s ongoing mission to be the most dependable platform for purchasing digital software online.

At a time when concerns around counterfeit licenses, shady software vendors, and rising costs are mounting, Gosoftware is taking bold steps to raise the bar. These initiatives include stronger verification protocols, enhanced buyer education, clearer license transparency, and a fortified customer support infrastructure.

“We believe that every customer deserves software that’s not only affordable but also authentic, secure, and easy to install,” said a Gosoftware spokesperson. “These new initiatives are about elevating trust and improving the full software-buying experience—from product selection to post-purchase support.”

Gosoftware has always prioritized legitimacy and reliability. In 2025, the company is doubling down on those values by implementing more rigorous product sourcing standards and license audits. All software licenses sold through Gosoftware will undergo updated verification protocols to ensure they meet Microsoft’s standards for authenticity and end-user safety.

Moreover, customers will benefit from a more transparent buying process. Each product page now includes clearer language on license type (OEM, Retail, Volume), compatibility information, and step-by-step installation guidance, making it easier than ever to make informed decisions.

As part of its new customer-focused initiatives, Gosoftware is also expanding its support system. Buyers now have access to:

  • Live Chat with Trained Software Experts

  • Free Installation Assistance via Remote Screen Share

  • In-Depth Software Guides and Troubleshooting Articles

This blend of human support and self-help tools ensures that every customer, whether an individual user or an IT professional, can activate and use their software confidently.

“Support should never be an afterthought,” said the spokesperson. “We’re building our support services to be as responsive and useful as the products we sell.”

In an increasingly saturated marketplace, many software buyers are tempted by unusually low prices, often unaware they’re purchasing counterfeit or unauthorized licenses. Gosoftware’s 2025 efforts include a customer education campaign to help users spot red flags and understand the real value of buying legal software.

By offering competitive pricing without compromising on legitimacy, Gosoftware aims to redefine the expectations around affordability and security in software purchasing.

Whether it’s a student looking for a Microsoft Office license, a small business upgrading to Windows 11 Pro, or a company seeking bulk licensing for its workforce, customers can now shop with added confidence. The enhancements not only improve the user experience but also solidify Gosoftware’s position as a trusted partner in digital software procurement.

“We don’t just sell software—we build long-term trust,” the spokesperson said. “That’s what these initiatives are about.”

With these new initiatives in place, Gosoftware invites new and returning customers to explore the enhanced platform, learn more about secure software purchasing, and take advantage of affordable pricing on top brands like Microsoft, Adobe, and more.

Customers can visit their website mentioned below to view the full catalog of products and experience the updated support and security features firsthand.

About Gosoftware

Gosoftware is a leading online software retailer specializing in authentic, affordable licenses for Microsoft Office, Windows operating systems, antivirus software, and more. With fast digital delivery, expert support, and a strong commitment to security and transparency, Gosoftware helps individuals and businesses get the software they need, without the guesswork.

Contact Details

Website: https://Gosoftwarebuy.com/

Email: support@Gosoftwarebuy.com

Address: 651 N Broad St, Suite 206, Middletown, DE 19709 USA

Media Contact

Company Name:-Go Software

Email:-marketing@gosoftwareus.com

Company Website:-https://gosoftwarebuy.com/

Toronto, Canada, 19th August 2025, ZEX PR WIRE, In an era where conversations about decolonization and ethical research practices are reshaping academic landscapes, Dr. Lindsay Martel Montgomery, Associate Professor of Anthropology at the University of Toronto, is at the forefront of a movement that aims to fundamentally change how archaeology and heritage preservation are practiced. With her pioneering work on Indigenous data sovereignty, Dr. Montgomery is helping to redefine the relationship between researchers and Indigenous communities by moving from extraction to collaboration, and from ownership to empowerment.

Recognized nationally and internationally as a leading voice in community-engaged archaeology, Dr. Montgomery’s research and advocacy efforts are driving a shift toward culturally sensitive, ethically grounded practices that empower Indigenous peoples to tell their own stories and safeguard their own heritage.

A Scholar Bridging Worlds

Holding a Ph.D. in Anthropology from Stanford University, Dr. Montgomery has cultivated a unique academic and professional trajectory that blends rigorous archaeological and historical methods with  community collaboration. Her research spans the breadth of North America and focuses on integrating oral histories, traditional ecological knowledge, and Indigenous epistemologies into archaeological narratives.

Now based at one of Canada’s most prestigious institutions, Dr. Montgomery has become a trusted advisor to organizations, museums, and educational institutions seeking to engage with Indigenous heritage in meaningful and respectful ways.

“Archaeology has long been a field shaped by colonial power structures,” Dr. Montgomery explains. “My goal is to help dismantle those structures by creating models for research that are collaborative, culturally relevant, and grounded in Indigenous sovereignty over cultural knowledge and data.

Redefining Archaeology Through Indigenous Data Sovereignty

At the core of Dr. Montgomery’s work is the concept of Indigenous data sovereignty (IDS), the right of Indigenous peoples to control the collection, interpretation, and dissemination of data that pertains to their communities, lands, languages, and histories.

This principle challenges conventional models of archaeological research, where findings are often removed from communities, housed in distant archives or museums, and interpreted through Western frameworks. Instead, Dr. Montgomery advocates for approaches where Indigenous partners are not just the subjects of study but co-curators and co-authors throughout the research process.

Her projects emphasize:

  • Collaborative research planning and informed consent before any excavation or study begins.

  • Culturally appropriate storage and use protocols of data, including artifacts, digital records, and field notes.

  • Community-centered dissemination, ensuring findings are shared first and foremost with the communities involved.

  • Commitment to long-term partnership building, that responds to the changing needs and goals of communities.

Through this work, Dr. Montgomery is helping to build models of decolonial practice that are already influencing academic programs, museum policies, and institutionalguidelines on heritage management.

Consulting, Advocacy, and Leadership Beyond Academia

While her roots are in academia, Dr. Montgomery’s impact extends far beyond the university classroom. She consults regularly with:

  • Nonprofit organizations working to preserve Indigenous languages and cultural heritage.

  • Museums seeking to decolonize their collections and curatorial practices.

  • Universities reimagining research ethics boards and curriculum design.

Her recent work includes developing ethical fieldwork frameworks for cultural heritage projects, training studentsin respectful collaboration with Indigenous communities, and contributing to international conversations on repatriation and digital data sovereignty.

Dr. Montgomery’s ability to navigate institutional policy and community priorities has made her a sought-after advisor and public speaker. Her contributions have been featured on platforms such as IdeaMensch and in interviews like “Getting to Know Professor Lindsay Martel Montgomery,” where she shares her philosophy of leadership, justice, and shared stewardship.

National and International Recognition

Dr. Montgomery’s contributions to Indigenous heritage research have earned her prestigious grants and fellowships from organizations such as the:

  • Wenner-Gren Foundation, supporting anthropological research that challenges conventional thought.

  • National Science Foundation, funding innovative archaeological field research that enhances understanding of the past

  • Social Sciences and Humanities Research Council of Canada (SSHRC), which backs innovative social science projects with national impact.

These accolades reflect the academic excellence, cultural relevance, and transformative potential of Dr. Montgomery’s work. But for her, the most meaningful recognition comes from the communities she partners with.

“True success,” she says, “is when a community feels that a project has supported their goals, respected their knowledge systems, and left something of value behind.”

The Future of Archaeology: Ethical, Equitable, and Indigenous-Led

Dr. Montgomery envisions a future where archaeology is no longer an extractive colonial enterprise, but a field of shared knowledge production that uplifts Indigenous voices and narratives. Her vision includes:

  • Supporting the next generation of Indigenous scholars through mentorship and inclusive research opportunities.

  • Promoting curriculum reform in anthropology and archaeology programs to include community-engaged methodologies and Indigenous philosophies.

  • Helping institutions establish policies of accountability and transparency, particularly regarding how they collect, use, and store cultural data.

“We must build a field where research is not done about communities but with them—and, ideally, led by them,” she emphasizes.

To that end, Dr. Montgomery continues to develop training materials, ethical toolkits, and strategic partnerships designed to equip researchers, students, and institutions with the knowledge and resources to engage in culturally responsible work.

Speaking, Teaching, and Transforming Systems

In addition to her scholarship and consulting work, Dr. Montgomery is a dynamic educator and speaker who brings her passion for ethical archaeology to conferences, classrooms, and public forums across North America.

Her lectures focus on topics such as:

  • The colonial history of archaeology and its modern-day consequences.

  • The principles and practice of Indigenous data sovereignty.

  • Strategies for building equitable partnerships between researchers and communities.

  • The role of storytelling, oral tradition, and Indigenous epistemologies in reshaping archaeological narratives.

As part of her commitment to accessibility and public scholarship, she continues to engage through interviews, workshops, and community events that demystify academic research and promote cross-cultural understanding.

Conclusion: A Champion for Change

In a time when institutions are being called to reflect, reform, and redress historic wrongs, Dr. Lindsay Martel Montgomery’s work is both timely and transformative. Her efforts to center Indigenous voices in archaeology represent not only a shift in method but a deeper shift in values toward respect, reciprocity, and repair.

From rural field sites to boardroom policy discussions, Dr. Montgomery is changing how we understand cultural heritage and who gets to define it.

For more information about Dr. Montgomery’s work, speaking engagements, or collaborative opportunities, visit the University of Toronto Department of Anthropology or connect via https://lindsay-montgomery.com/ 

Toms River, NJ, 19th August 2025, ZEX PR WIRE, BlackBird Financial LP, led by Judah Spinner, CFA, is pleased to  announce its recent investment in Lululemon Athletica (NASDAQ: LULU). The firm’s  investment highlights its view that Lululemon’s market leadership and brand strength are paired  with what they see as an attractive and undervalued entry point, offering a compelling  opportunity to invest in a truly exceptional company. 

“Lululemon is a standout in the retail world,” said Judah Spinner, Founder and Chief Investment  Officer of BlackBird Financial LP. “They have built an incredibly strong brand name and are the  clear leader in their category. What’s more, their sales per square foot are among the highest in  the industry. Because of the industry’s recent slowdown, many investors have turned more  pessimistic, allowing us to purchase Lululemon at what we believe is a very favorable  valuation.” 

Competitive and Market Leadership 

Lululemon has carved out a dominant position in the athleisure and activewear market. The  company’s brand recognition is second to none, and its retail operations consistently deliver  exceptional sales per square foot. Lululemon’s growth in China has been particularly impressive,  and the brand has successfully expanded its presence in Europe as well. Moreover, while  menswear currently represents a smaller portion of overall sales, it is growing rapidly and  represents a significant growth avenue for the future. 

Company Background and Leadership 

Lululemon was founded in 1998 by Chip Wilson in Vancouver, Canada. Originally established  as a design studio by day and a yoga studio by night, the company quickly evolved into a leading  global brand in the athleisure market. Over the years, Lululemon has become synonymous with  high-quality activewear and a loyal customer base that spans the globe. 

Since 2018, the company has been led by CEO Calvin McDonald. McDonald brought a wealth  of retail experience to Lululemon and has been instrumental in guiding the company through a  period of robust growth and international expansion. Under his leadership, Lululemon has not  only strengthened its core product lines but also expanded into new categories and markets. 

“We have immense confidence in Calvin McDonald and his vision for Lululemon’s future,” Spinner noted. “He has articulated a clear strategy focused on innovation, customer experience,  and international growth. We believe in the direction he’s taking the company and are excited to  support Lululemon as it continues to thrive.” 

Financial Performance and Capital Discipline 

Lululemon has demonstrated strong financial management. While the company made a notable  misstep with its 2020 acquisition of Mirror, a home-fitness startup purchased for $500 million, 

the outcome of that deal did not meet expectations. By the end of fiscal year 2022, Lululemon  recorded a post-tax impairment charge of approximately $442.7 million, effectively writing off  most of the acquisition and eventually shutting down its operations. 

Nevertheless, Lululemon has otherwise been disciplined in capital allocation. Over the past three  years, the company has repurchased a total of roughly 6.6 million shares, spending  approximately $1.9 billion on buybacks. This has reduced the share count significantly,  enhancing shareholder value and demonstrating the company’s commitment to returning capital  to investors. In fiscal year 2024, Lululemon reported net revenue of $10.6 billion, a 10% increase  from the previous year, while net income grew by 17% to $1.8 billion, both record highs for the  company. 

Strategic Growth and Future Potential 

Looking ahead, BlackBird sees significant growth potential for Lululemon, not only in its  established markets but also through continued expansion in Europe and further penetration of  the men’s segment. The company’s ability to innovate and outperform competitors sets it apart.  Management has focused on maintaining strong cash flows, and despite the disastrous Mirror  acquisition, they have continued to execute well on their long-term strategy. 

“We think Lululemon’s future remains very bright,” Spinner concluded. “They make excellent  products, have a loyal customer base, and are well-positioned to grow in multiple regions. We’re  confident in their leadership and excited to be long-term partners as they continue to execute.” 

About BlackBird Financial LP 

BlackBird Financial LP, founded by Judah Spinner, is a value-oriented investment firm that  adheres to the Graham-and-Dodd school of investing. They focus on identifying structurally  advantaged businesses and purchasing them at prices well below their intrinsic value.  

In the first half of 2025, BlackBird delivered a net return of 34.4%, significantly outpacing the  S&P 500’s 6.1% return. This performance underscores their commitment to disciplined value  investing and their ability to find opportunity where others overlook it.

To learn more visit: https://blackbirdfinancial.com/

Brisbane, Australia, 19th August 2025, ZEX PR WIRE, Innovation in healthcare often arises from a simple yet profound need, to cater to differences in individual care. For Australians seeking personalized solutions in anaesthetics, My Compounding Pharmacy has emerged as a trusted partner for both patients and doctors alike. With a unique blend of science, artistry, and a deeply rooted commitment to patient well-being, this pharmacy has transformed the way anaesthetic medications are developed and delivered.

Why Personalization Matters in Anaesthetics 

The practice of administering anaesthesia is rarely one-size-fits-all, and for good reason. The nuances of each procedure, patient sensitivity, and even the duration of treatment demand precision and personalization. This is where compounded anaesthetic medications step in to fill the gap left by standardized solutions. 

Patients undergoing tattoo removal, laser rejuvenation, or skin needling, for instance, might experience differing levels of sensitivity or require varying levels of numbing. Compounded anaesthetics provide the flexibility to modify both strengths and compositions, adjusting for specific patient needs with pinpoint accuracy. My Compounding Pharmacy has positioned itself as an authority in this specialized area, offering tailored formulations for a wide variety of procedures. 

The Art and Science of Compounded Anaesthetics 

Unlike mass-manufactured medicines, compounded anaesthetics are developed with the individual at the center. These formulations balance medical science with creative problem-solving, yielding solutions that are as unique as the patients who use them. 

For example, patients or doctors can work closely with the pharmacy to design anaesthetics with concentrations as high as 30% for more complex procedures or consult with pharmacists to create milder formulations without the need for a prescription. This flexibility removes barriers, offering comfortable, accessible solutions tailored to each unique situation. 

Furthermore, the inclusion of agents like epinephrine in formulations adds another layer of customization, allowing doctors to enhance the procedure by minimizing bleeding and prolonging the numbing effect. These adaptations not only improve comfort but also optimize procedural efficacy. 

A Commitment to Excellence 

What truly sets My Compounding Pharmacy apart is its dedication to maintaining the highest standards of quality and safety. Every formulation adheres to stringent regulatory guidelines established by the Pharmacy Board of Australia and the Therapeutic Goods Administration (TGA). This ensures that each compound surpasses safety benchmarks while delivering effective and reliable results for patients. 

The pharmacy’s team, boasting over 85 years of combined experience, brings unparalleled expertise to the table. Their meticulous approach to testing and quality control offers peace of mind to both doctors and patients. Every ingredient used is carefully selected and rigorously checked for efficacy, ensuring that the final product is nothing short of exceptional. 

Bridging the Gap for Doctors and Patients 

Healthcare professionals, especially those in fields like dermatology, dentistry, and cosmetic treatments, often face challenges that standardized medications can’t solve. From complex cases to patients with unique sensitivities, the need for precise solutions is growing. 

My Compounding Pharmacy has stepped in as an invaluable partner to practitioners across Australia. By collaborating with specialists, they enable doctors to provide tailored treatments that improve patient experiences and outcomes. Whether it’s creating allergen-free formulations or suggesting alternatives to discontinued medications, their work empowers clinicians to deliver care without compromising on quality. 

For patients, the pharmacy’s approach transforms what can often be an intimidating process into one that prioritizes comfort and clarity. With options for both prescription and non-prescription anaesthetic solutions, they ensure that no individual is left without the support they need. 

Redefining Patient-Centered Care 

The heart of My Compounding Pharmacy’s mission lies in creating a seamless and supportive experience for their patients. They’ve redefined accessibility, offering online consultations and free 3-minute calls with pharmacists for those who need guidance but lack a prescription. By adapting to patients’ lifestyles and needs, they’ve made advanced healthcare solutions feel tangible and close at hand. 

This personalized approach is why the pharmacy has accrued over 100 five-star reviews, with countless testimonials lauding their responsiveness, expertise, and ability to provide unmatched care. But beyond accolades, it’s their human-centered philosophy that makes them a standout choice for anaesthetic medications in Australia. 

The Future of Compounded Anaesthetics 

The demand for tailored medications will only grow as healthcare continues to evolve. With advancements in both medical technology and patient expectations, compounding pharmacies like My Compounding Pharmacy will remain crucial in bridging the gap between standardized care and personalized medicine. 

For doctors, the pharmacy offers innovative solutions to challenging cases, enabling them to offer more precise and impactful treatment plans. For patients, it provides an opportunity to approach procedures free from the fear of discomfort, knowing their unique needs will be addressed with care and expertise. 

Start Your Journey to Comfort 

Whether you’re preparing for a cosmetic procedure or a medical treatment, the right anaesthetic can transform your experience. My Compounding Pharmacy is here to ensure that your path to comfort begins with high-quality, customized solutions tailored specifically to your needs. 

If you’re a doctor looking for a trusted partner or a patient seeking expert guidance, connect with My Compounding Pharmacy today. Discover the difference that personalized anaesthetic medications can make in your healthcare journey. 

To learn more visit: https://mycompounding.com.au/

SHENZHEN, CHINAOn 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.

The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.

According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.

“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum

At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.

To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.

Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.

Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.

CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.

 

Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth

According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.

Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.

In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.

Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

SHENZHEN, CHINAOn 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.

The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.

According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.

“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum

At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.

To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.

Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.

Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.

CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.

 

Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth

According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.

Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.

In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.

Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.